Deimination of the myelin basic protein decelerates its proteasome-mediated metabolism
- 1 July 2016
- journal article
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 469 (1) , 277-280
Abstract
Deimination of myelin basic protein (MBP) by peptidylarginine deiminase (PAD) prevents its binding to the proteasome and decelerates its degradation by the proteasome in mammalian cells. Potential anticancer drug tetrazole analogue of chloramidine 2, at concentrations greater than 1 µM inhibits the enzymatic activity of PAD in vitro. The observed acceleration of proteasome hydrolysis of MBP to antigenic peptides in the presence of PAD inhibitor may increase the efficiency of lesion of the central nervous system by cytotoxic lymphocytes in multiple sclerosis. We therefore suggest that clinical trials and the introduction of PAD inhibitors in clinical practice for the treatment of malignant neoplasms should be performed only after a careful analysis of their potential effect on the induction of autoimmune neurodegeneration processes.Keywords
This publication has 15 references indexed in Scilit:
- Ubiquitin‐independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunityThe FASEB Journal, 2015
- Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome SystemCurrent Cancer Drug Targets, 2014
- Multiple Sclerosis Autoantigen Myelin Basic Protein Escapes Control by Ubiquitination during Proteasomal DegradationJournal of Biological Chemistry, 2014
- Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S ProteasomeBioMed Research International, 2014
- Multiple sclerosisJournal of Clinical Investigation, 2012
- Pathogenic CD8 T Cells in Multiple Sclerosis and Its Experimental ModelsFrontiers in Immunology, 2012
- Naturally Presented Peptides on Major Histocompatibility Complex I and II Molecules Eluted from Central Nervous System of Multiple Sclerosis PatientsMolecular & Cellular Proteomics, 2009
- Structural insight into the role of myelin basic protein in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of ConstructionPhysiological Reviews, 2002
- Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.Journal of Clinical Investigation, 1993